LIFE NIS, GERD-Patients - Evaluation of Burden of Disease Determined by GERD Impact Scale (GIS)

Completed

• Conditions: GERD

• Registration Number: NCT00567619
• Lead Sponsor: AstraZeneca

Brief Summary

Evaluate burden of disease in Patients with newly occurred upper GI symptoms related to GERD (symptom frequency \& severity, QoL, lifestyle modifications, self-medication) - baseline data according to GERD impact scale presenting to specialists, especially internists

- Evaluate effect of treatment with a acid suppressive therapy on these parameters: looking for improvement of symptom burden and quality of life according to the GERD impact sca

Detailed Description

Not available

Study Timeline

• Study Start: 2007-07
• Study First Submitted: 2007-09-20
• Study First Submitted QC: 2007-12-04
• Study First Posted: 2007-12-05
• Status Verified: 2008-02
• Last Update Submitted: 2008-02-14
• Last Update Posted: 2008-02-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 900

Inclusion Criteria

• Patients with newly occured upper GI symptoms related to GERD

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Research Site; 🇦🇹 Vienna, Austria